Pharmaceutical C-suite update
With two knighthoods in the last month, here EPR discusses…
With two knighthoods in the last month, here EPR discusses five developments in the drug development community’s C-suite.
List view / Grid view
With two knighthoods in the last month, here EPR discusses…
With two knighthoods in the last month, here EPR discusses five developments in the drug development community’s C-suite.
The study will now assess the tolerability and safety of…
The study will now assess the tolerability and safety of multiple ascending doses of PF-07321332, Pfizer’s investigational oral antiviral agent against SARS-CoV-2.
Pfizer Inc. and Cellectis announced that they have entered into…
19 June 2014 | By Pfizer
Pfizer Inc. and Cellectis announced that they have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets...
Pfizer Inc. announced the opening of a new 280,000 square-foot…
16 June 2014 | By Pfizer
Pfizer Inc. announced the opening of a new 280,000 square-foot Research and Development hub in Cambridge, Mass...
Lead program includes novel investigational compound for prevention/treatment of skin…
22 November 2011 | By Pfizer
Lead program includes novel investigational compound for prevention/treatment of skin scarring...
10-year lease marks a strategic partnership between the academic research…
21 November 2011 | By Pfizer
10-year lease marks a strategic partnership between the academic research community and industry to boost innovation...
View and listen to a webcast of a presentation by…
10 March 2011 | By Pfizer
View and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide R&D...